Plerixafor (trade name Mozobil) is an immunostimulant used to mobilize Hematopoietic Stem cells in cancer patients into the bloodstream. The stem cells are then extracted from the blood and transplanted back to the patient.
Peripheral blood stem cell mobilization, which is important as a source of hematopoietic stem cells for transplantation, is generally performed using granulocyte colony-stimulating factor (G-CSF), but is ineffective in around 15 to 20% of patients. Combination of G-CSF with plerixafor increases the percentage of persons that respond to the therapy and produce enough stem cells for transplantation. The drug is approved for patients with lymphoma and multiple myeloma. Since our commencement in this domain, we have been engaged in providing the finest grade MOZOBIL.